Therapeutics Development Core (Core B)

治疗开发核心（核心B）

• 批准号: 9753229
• 负责人: Xunrong Luo
• 金额: $ 26.13万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9753229
• 关键词: Animal Model; Biological; Biological Sciences; Blood Vessels; Cells; Chemicals; Chemistry; Chronic Kidney Failure; Clinical; Clinical Trials; Collaborations; Consultations; Development; Developmental Process; Developmental Therapeutics Program; Diabetes Mellitus; Diabetic Nephropathy; Disease; Doctor of Philosophy; Drug Kinetics; Drug Targeting; End stage renal failure; Feedback; Funding; Future; Goals; Hematology; Hematopoietic; Human; In Vitro; Income; Infrastructure; Institutes; Intercept; International; Islets of Langerhans; Kidney; Kidney Diseases; Licensing; Life; Medical Device; Mentors; Modality; Molecular; Nanotechnology; Neurologic; Organ; Pathogenesis; Pharmaceutical Preparations; Phenotype; Pre-Clinical Model; Prevention; Process; Production; Quality Control; Recombinant Proteins; Renal function; Replacement Therapy; Research Personnel; Risk; Route; Services; Stem cells; Supportive care; System; Testing; Therapeutic; Tissues; Toxicology; Translating; Translations; Transplantation; Treatment Efficacy; Universities; Validation; base; clinical care; clinical translation; commercialization; design; drug discovery; experience; high throughput screening; immunoregulation; in vivo; in vivo imaging; in vivo monitoring; innovation; kidney repair; nanomedicine; novel; novel therapeutics; product development; programs; regenerative therapy; restoration; scale up; screening; small molecule; small molecule therapeutics; synergism; targeted treatment; technology development; therapeutic development; therapeutic target; tool; virtual

PROJECT SUMMARY TO THERAPEUTICS DEVELOPMENT CORE The goal of the Therapeutics Development Core (Core B) is to establish an efficient platform for supporting the development and validation of a pipeline of chemical, biological, and cellular therapeutics for the treatment of a wide spectrum of kidney diseases. Northwestern University (NU) has been at the forefront of drug discovery for a wide range of diseases, and state-of-the-art infrastructures have been built that collectively have significantly expanded our therapeutics armamentarium for many diseases including hematological, oncological, neurological, and rheumatological conditions. However, they have not been prioritized and tailored to kidney-specific therapeutics development. We propose to fill this gap by establishing a Therapeutics Development Core within the NU-GoKIDNEY Center. The Therapeutics Development Core will function as an efficient translational conduit between the Preclinical Models Core (Core A) and the Clinical and Translational Core (Core C). This Core proposes to provide a “one-stop” shop for concierge services for access and expert guidance to kidney therapeutics development, with the ultimate goal of clinical translation. It will be constructed to provide centralized consultation services for developing novel kidney disease-specific therapeutics to the NU-GoKIDNEY Center investigators for: (1) designing and testing experimental biological and small molecule therapeutics; (2) designing and testing cellular therapeutics; and (3) designing and testing nanotechnology-based precision targeting of therapeutic “payloads” to the desired cells and tissues. Core B will implement a Ph.D.-level Navigator system for maximizing service efficiency and promoting innovative collaborations. Core B will also use the soon-to-be-launched nephro-HUB to expand the core user base, track core services, enhance user interactions and promote user collaborations. Core B Directors and Navigators collectively possess extensive expertise encompassing novel cellular therapeutics development, virtual drug and biologics design, high-throughput screening platforms for efficiency determination, and nanotechnology-based precision drug targeting. Core B will formalize and capture this collective expertise under one roof, and provide investigators of the NU-GoKIDNEY Center with superior customer service combined with expert guidance in choosing the most efficient route for novel therapeutics development. By providing these core services, we anticipate that the Therapeutics Development Core will: (1) accelerate kidney therapeutics development by providing target-specific consultations and navigation through the processes of therapeutics design, development, validation and production; (2) elevate kidney disease- specific therapeutics development to the forefront of existing cutting-edge expertise and state-of-the-art infrastructures in therapeutics development at Northwestern; (3) catalyze and synergize innovative collaborations within a dynamic network of NU-GoKIDNEY Center investigators via a common platform provided by the Therapeutics Development Core.

治疗开发核心的项目摘要 治疗性开发核心（核心B）的目标是建立一个有效的平台 支持化学，生物学和细胞管道的开发和验证 治疗多种肾脏疾病的治疗方法。西北大学（NU）有 我们处于各种疾病的药物发现的最前沿，最新的基础设施有 建造的，该建造统称为许多疾病大大扩展了我们的治疗方法 包括血液学，肿瘤学，神经系统和流变学条件。但是，他们没有 我们建议通过 在NU-Gokidney中心建立治疗发展核心。治疗学 开发核心将充当临床前模型核心（核心）之间的有效翻译管道 A）以及临床和转化核心（核心C）。此核心提议为提供一家“一站式”商店 礼宾服务，用于肾脏疗法开发的访问和专家指导，最终目标是 临床翻译。它将被构建以提供集中的咨询服务以开发新颖 NU-Gokidney中心研究人员的肾脏疾病特异性治疗：（1）设计和测试 实验生物学和小分子疗法； （2）设计和测试细胞疗法；和 （3）设计和测试基于纳米技术的精确靶向所需的治疗“有效载荷” 细胞和组织。核心B将实施博士学位级导航器系统，以最大化服务效率和 促进创新的合作。核心B还将使用即将发射的肾枢纽来扩展 核心用户基础，跟踪核心服务，增强用户交互并促进用户协作。核心b 董事和导航员统称具有广泛的专业知识，包括新的蜂窝疗法 开发，虚拟药物和生物制剂设计，高通量筛选平台以提高效率 确定和基于纳米技术的精确药物靶向。核心B将形式化并捕获 一个屋顶下的集体专业知识，并为Nu-Gokidney中心的调查员提供上级 客户服务与专家指导相结合，选择了最有效的新型治疗途径 发展。通过提供这些核心服务，我们预计Therapeutics开发核心将：（1） 通过提供特定于目标的咨询和导航，加速肾脏疗法开发 理论设计，发展，验证和生产的过程； （2）提升肾脏疾病 - 特定的治疗剂开发到现有的尖端专业知识和最先进的最前沿 西北地区治疗开发基础设施； （3）催化和协同创新 NU-Gokidney中心调查员通过一个公共平台的动态网络进行合作 由Therapeutics开发核心提供。